ERBB2 and breast carcinoma: A very recent preclinical study in fact showed that regression of HER2-positive breast cancer PDX models with the potent H1047 PIK3CA mutations could only be achieved with the addition of everolimus to neratinib, but not with neratinib alone25,26.